Genetics and epigenetics of myelodysplastic syndromes and response to drug therapy: new insights

Saeid Shahrabi, Abbas Khosravi, Mohammad Shahjahani, Fahher Rahim, Najmaldin Saki

1Department of Biochemistry and Hematology, Semnan University of Medical Sciences, Semnan; 2Health Research Institute, Thalassemia and Hemoglobinopathy Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz; 3Golestan Hospital Clinical Research Development Unit, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

Abstract

Myelodysplastic syndromes (MDS) are a heterogeneous group of hematologic neoplasms occurring mostly in the elderly. The clinical outcome of MDS patients is still poor despite progress in treatment approaches. About 90% of patients harbor at least one somatic mutation. This review aimed to assess the potential of molecular abnormalities in understanding pathogenesis, prognosis, diagnosis and in guiding choice of proper therapy in MDS patients. Papers related to this topic from 2000 to 2016 in PubMed and Scopus databases were searched and studied. The most common molecular abnormalities were TET2, ASXL1 as well as molecules involved in spliceosome machinery (U2AF1, SRSF2 and SF3B1). Patients with defects in TET2 molecule show better response to treatment with azacitidine. IDH and DNMT3A mutations are associated with a good response to decitabine therapy. In addition, patients with del5q subtype harboring TP53 mutations do not show a good response to lenalidomide therapy.

In general, the results of this study show that molecular abnormalities can be associated with the occurrence of a specific morphological phenotype in patients. Therefore, considering the morphology of patients, different gene profiling methods can be selected to choose the most appropriate therapeutic measure in these patients in addition to faster and more cost-effective diagnosis of molecular abnormalities.

Introduction

Myelodysplastic syndromes (MDS) form a heterogeneous group of bone marrow (BM) disorders that often occur in the elderly and in those who have had a history of contact with cytotoxic agents. These patients generally have varying cytopenia in different lineages due to ineffective hematopoiesis. Morphological dysplasia in BM as well as acute myelogenous leukemia (AML) transformation occurs in a third of patients. Diagnosis of MDS is still based on the assessment of peripheral blood smear, blood cell count, BM aspiration and biopsy to evaluate the cellularity and fibrosis.

Treatment of MDS patients is different based on their prognosis score, ranging from simple supportive care such as blood transfusion to advanced treatments like BM transplantation. Currently, three chemotherapeutic drugs have been approved by FDA, including azacitidine and decitabine as the first-line therapy for all subgroups of MDS as well as Lenalidomide for MDS with 5q deletion, which can improve hematopoiesis, delay disease progression, increase survival and improve quality of life in a number of patients. It should be noted that allogeneic hematopoietic stem cell transplantation is the only potentially curative therapy for MDS patients, but it is useful only for a limited number of patients given the usually advanced age of patients. Different prognosis systems have also been suggested for MDS patients that classify patients based on the number of cytopenic lineages, percentage of BM blasts and cytogenetic abnormalities. Pathophysiology of MDS is a manifold process in which cytogenetic changes, gene mutations (or both) as well as extensive gene hypermethylation in advanced stages of the disease are involved. Somatic mutations commonly arise in MDS patients and are associated with a number of clinical features in patients, including p53 and NRAS mutations that are strongly correlated with severe thrombocytopenia. It has also been shown that different genes are mutated during ageing, which are generally associated with transformation to myeloid/lymphoid leukemia, including TET2, DNMT3A, ASXL1 and SF3B1. This may be a reason for the incidence of MDS in seventh and eighth decades of life. However, the prognosis system of these mutations has not been taken into account and since these mutations generally occur in genes.
encoding spliceosome components, chromatin remodeling genes, epigenetic pattern regulators as well as transcription factors, their use in target therapy is faced with problems. It seems that progress in treatment of MDS patients is dependent upon accurate identification of disease mechanisms; therefore, attempts to improve current therapeutic methods should be based on understanding specific disease-causing mechanisms. There are several obstacles in the use of gene mutations as therapeutic targets as well as diagnostic markers of disease. Gene mutations are involved in MDS pathogenesis and have a high potential for guiding proper choice of therapeutic approach for patients. This study thus aimed to identify the role of gene mutations involved in MDS pathogenesis as well as ability of specific gene mutations to predict response to different drugs in case of multiple mutations.

**Genetic and epigenetic abnormalities**

Development of next generation sequencing (NGS) techniques led to detection of somatic gene mutations in approximately 90% of MDS patients. The currently detected recurrent mutations involve nearly 30 genes, which are mainly classified in four functional groups (Table 1) listed.

**Oncogenes and tumor suppressors**

**TP53:** p53 protein is a transcription factor expressed by TP53 gene in 1p13.1 locus. This protein acts as a tumor suppressor regulating gene expression in response to stress signals of the cell, which leads to induction of cell cycle arrest, apoptosis, aging, DNA repair or changes in cellular metabolism. TP53 mutation is common in solid tumors and has been reported as a common mutation in hematologic malignancies to a lesser extent. Mouse double minute 2 homolog (MDM2) bind to and inhibits function of p53. Deregulation of p53 pathway is either secondary to mutation in TP53 gene or due to changes in the expression of its inhibitor of MDM2. Although TP53 mutation is observed in about 10% of all MDS patients, it is seen in 20% of del5q and in over 70% of complex karyotype patients, respectively. However, increased expression of MDM2 is observed only in 10% of MDS patients. The importance of p53 mutation in del5q subtype is related to RPS 14. This protein, which binds and inhibits MDM2, is subject to reduced expression in del5q. Therefore, when p53 mutation occurs along with del5q, p53 pathway is dysregulated in two ways. It has also been shown that this mutation is associated with thrombocytopenia and increased blasts, which is a predictor of poor prognosis in MDS patients.

**N/R RAS:** Members of RAS protein family include N-Ras, K-RAS and H-RAS. As a vital hub, Ras-GTPases are involved in several signaling pathways and play a role in regulating different cellular processes, including proliferation, differentiation, self-renewal and apoptosis. Activating mutations or Ras gene amplification is observed in nearly a third of human cancers. These mutations lead to non-ligand-dependent activation of signaling pathways, leading to increased cell proliferation. Mutations involving Ras genes, most notably NRAS, are observed in 5-10% of MDS patients; however, the prevalence of this mutation is up to 30% in patients with isolated isochromosome 17 [1 (17q)]. These mutations have been associated with poor prognosis in the majority (but not all) the studies. NRAS mutation also seems to play an important role in AML transformation of these patients, such that 26% of AML patients showed this mutation at the time of transformation.

**Ectropic viral integration site 1 (EVI1):** EVI1 gene (3q26) is expressed in a low level in normal blood and BM cells. EVI1 is a zinc finger protein regulating the activity of transcription factors during different events. This protein regulates various cellular mechanisms such as proliferation, differentiation and apoptosis. EVI1 causes changes in the activity of transcription factors and signaling pathways, including GATA and Runx-related transcription factor 1 (RUNX1). GATA1 is an essential transcription factor in erythropoiesis and megalakroyposis, and EVI1 can inhibit GATA-1 dependent erythropoiesis as an antagonist. In addition, EVI1 suppresses the PU.1 and RUNX1 transcription factors involved in myeloid differentiation through interaction with them, ultimately disrupting the expression of genes involved in terminal myeloid differentiation. EVI1 also regulates the maintenance and repopulation of hematopoietic stem cells as well as HSCs transformation into leukemic cells via interaction with GATA2 and phosphatase and tensin homolog (PTEN) transcription factors. Therefore, EVI1 generates leukemic cells in addition to suppressing the differentiation and maturation of erythrocytes, megakaryocytes and myeloid cells. Abrupt expression of EVI1 has been observed in BM of AML patients and approximately 10% of MDS patients. These patients generally have a poor prognosis and show manifestations of multi-lineage dysplasia, severe anemia and general cytopenia. It is also noteworthy that increased expression of EVI1 is observed in chromosomal rearrangements involving 3q26. Moreover, it seems that aberrant expression of EVI1 is closely related with hypermethylation of P15 (a cyclin dependent kinase inhibitor) promoter in MDS patients, which results in decreased expression of P15 and interference with the cell cycle. These findings can indicate one of the most important mechanisms of MDS neoplasia by EVI1. Therefore, evaluation of the effect of HMA drugs on patients with increased expression of EVI1 can present valuable results.

**DNA methylation**

DNA methyltransferases (DNMTs): DNA methylation, the addition of a methyl group added to cytosine or adenine, is an epigenetic change that plays an important role in transcription regulation, chromatin remodeling and genomic instability. In general, DNA methylation tends to inhibit transcription. In cancers generally, tumor suppressor genes tend to be hypermethylated and oncogenes tend to be hypomethylated.

In fact, the pattern of DNA methylation determines chromatin structure, which is substantially changed in neoplasms. These epigenetic changes generally lead to promoter hypermethylation and the resulting aberrant silencing of genes, a process that can initiate tumor progression. DNA methyltransferases (DNMTs) are key DNA methylation enzymes, including DNMT1, DNMT3A and DNMT3B, which cause DNA methylation in carbon 5 of cytosine in CpG islands, which generates 5mC. 5mC causes steady inhibition of gene expression. DNMTs, especially DNMT3A, are subject to several mutations in hematologic malignancies, so that mutations involving DNMT3A have been observed in 7% of MDS patients. The mechanism by which DNMT3A results in leukemia is not clear, but this mutation seems to be insufficient to cause leukemia and only predisposes to it, while it interestingly occurs simultaneously with SF3B1 and U2AF1 mutations. These findings can imply coordination between these mutations to cause MDS. This mutation has been associated with poor prognosis as patients with DNMT3A mutation have lower overall survival and a higher risk of transformation to AML relative to those lacking it.

**Ten-eleven translocation 2 (TET2):** TET protein family (TET1, TET2 and TET3) includes dioxygenases related to Fe2+ and oxoglutarate that can oxidize 5mC to 5hmC, 5fC and 5caC in DNA and thus cause DNA demethylation. These proteins are therefore involved in different biological processes such as epigenetic regulation of gene transcription, embryonic development, stem cell function and leukemic transformation. It seems that each of these genes is expressed in a specific tissue in order to control a particular gene panel in that tissue. Among them, TET2 plays an important role in hematopoiesis and differentia-
tion induction of hematopoietic cells (40). TET2 is mutated in many hematologic malignancies and is one of the most common mutations found in MDS patients, so that 19-23% of patients show this mutation.41-43 TET2 mutations lead to loss of normal activity or decreased expression of this protein, and patients with these mutations show a sharp decline in 5hmC as well as 5mC accumulation.44,45 However, it is reported that this mutation is indicative of a good prognosis in MDS patients.46

Isocitrate dehydrogenase (IDH): IDH1 (2q33.3) and its mitochondrial homolog, IDH2 (15q26.1), which encode the enzymes active in the Krebs cycle. These enzymes cause oxidative decarboxylation of isocitrate and convert it to alpha-ketoglutarate.47 Mutations of these enzymes are of gain of function type and in their new form they trigger the production of 2-hydroxyglutarate.47 Accumulation of 2-hydroxyglutarate inhibits the alpha-ketoglutarate-dependent enzymes, including TET2. Therefore, IDH1/IDH2 mutations cause epigenetic defects similar to TET2 mutation, which impair myeloid differentiation and result in increased expression of stem/progenitor cell markers.48 Besides, the accumulation of 2-hydroxyglutarate leads to production of reactive oxygen species (ROS), damage to DNA, inhibition of Egg-laying defective Nine (EGLN) followed by stabilization of hypoxia-inducible factor 1a (HIF-1a).49,50 However, it has been shown that damage to DNA, especially activation of HIF-1a, plays an important role in pathogenesis of MDS.51,52 IDH mutations are seen in about 3-12% of MDS patients and are associated with poor clinical prognosis in these patients.53

**Histone modification**

Enhancer of zeste homolog 2 (EZH2): EZH2 is a histone methyltrans-

### Table 1. Common molecular defects in myelodysplastic syndromes.

<table>
<thead>
<tr>
<th>Oncogenes/ Tumor suppressor</th>
<th>Chromosome</th>
<th>Function</th>
<th>Incidence</th>
<th>Related chromosome</th>
<th>Morphologically subtype aberration</th>
<th>Clinical features</th>
<th>Prognosis</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>TP53</td>
<td>17p13.1</td>
<td>Tumor suppressor gene</td>
<td>10%</td>
<td>Complex karyotype, del5q</td>
<td>del5q</td>
<td>Higher blast count, blood transfusion dependent, severe thrombocytopenia</td>
<td>Poor</td>
<td>8,14</td>
</tr>
<tr>
<td>NRAS</td>
<td>1p13.2</td>
<td>Oncogene, GTPase</td>
<td>4%</td>
<td>i(17q)</td>
<td>-</td>
<td>Severe thrombocytopenia</td>
<td>Poor</td>
<td>8,21,88</td>
</tr>
<tr>
<td>EVI1</td>
<td>3q26</td>
<td>Transcriptional regulator and oncoprotein that interact with PU.1</td>
<td>10%</td>
<td>3q26</td>
<td>-</td>
<td>Severe anemia, multilineage myeloid dysplasia</td>
<td>Poor</td>
<td>29</td>
</tr>
<tr>
<td>TET2</td>
<td>4q24</td>
<td>Methylcytosine dioxygenase</td>
<td>19-23%</td>
<td>Normal</td>
<td>-</td>
<td>No significantly differ in clinical/hematologic parameters</td>
<td>Good</td>
<td>8,46</td>
</tr>
<tr>
<td>IDH1/IDH2</td>
<td>2q33.3, 15q28.1 (IDH2)</td>
<td>Catalyze the oxidative decarboxylation of isocitrate to 2-oxoglutarate</td>
<td>3.4-12.2%</td>
<td>Normal karyotype and RAEB-1/RAEB-2 -7/7q</td>
<td>-</td>
<td>Poor</td>
<td>47,53</td>
<td></td>
</tr>
<tr>
<td>DNMT3A</td>
<td>2p23.3</td>
<td>DNA methyltransferase</td>
<td>7.8%</td>
<td>Normal</td>
<td>-</td>
<td>No impact</td>
<td>Poor</td>
<td>36</td>
</tr>
<tr>
<td>EZH2</td>
<td>7q35-q36</td>
<td>Histone methyltransferase</td>
<td>6%</td>
<td>del7/7q</td>
<td>RAEB</td>
<td>Poor</td>
<td>56,57</td>
<td></td>
</tr>
<tr>
<td>ASXL1</td>
<td>20q11.1</td>
<td>Histone-binding protein</td>
<td>20%</td>
<td>Complex karyotypes, i(17q)</td>
<td>-</td>
<td>Poor</td>
<td>21,61,70</td>
<td></td>
</tr>
<tr>
<td>SF3B1</td>
<td>2q33.1</td>
<td>Splicing</td>
<td>10%</td>
<td>5 or 5q</td>
<td>RARS-T</td>
<td>Refractory anemia</td>
<td>Not predict</td>
<td>65,69-71</td>
</tr>
<tr>
<td>U2AF1</td>
<td>21q22.3</td>
<td>Splicing</td>
<td>15%</td>
<td>Trisomy 8 and del (20q)</td>
<td>CMML RAEB</td>
<td>-</td>
<td>Not predict</td>
<td>65,69-71</td>
</tr>
<tr>
<td>SRSF2</td>
<td>17q25.1</td>
<td>Splicing</td>
<td>13%</td>
<td>i(17q)</td>
<td>CMML RAEB</td>
<td>-</td>
<td>Poor</td>
<td>65,69-71</td>
</tr>
<tr>
<td>RUNX1</td>
<td>21q22</td>
<td>Transcription factor</td>
<td>12%</td>
<td>-7/7q</td>
<td>RAEB, RAEB-t</td>
<td>Higher neutrophil counts, severe thrombocytopenia</td>
<td>Poor</td>
<td>8,72-74</td>
</tr>
<tr>
<td>JAK2</td>
<td>9p24.1</td>
<td>Tyrosine kinase</td>
<td>50% in RARS</td>
<td>-</td>
<td>RARS</td>
<td>Poor</td>
<td>21,75-76</td>
<td></td>
</tr>
<tr>
<td>CBL</td>
<td>11q23.3</td>
<td>Targeting substrates for degradation by the proteasome</td>
<td>5% in CMML</td>
<td>-</td>
<td>CMML</td>
<td>-</td>
<td>Poor</td>
<td>77</td>
</tr>
<tr>
<td>RPS14</td>
<td>5q33.1</td>
<td>Ribosomal protein S14</td>
<td>100% in del 5q</td>
<td>del5q</td>
<td>del5q</td>
<td>Anemia</td>
<td>Not studied</td>
<td>22,79</td>
</tr>
</tbody>
</table>

*EV1, ecotropic viral integration site 1; TET2, ten-eleven translocation 2; IDH, isocitrate dehydrogenase; RAEB, refractory anemia with excess blasts; DNMT3A, DNA methyltransferase 3A; EZH2, enhancer of zeste homolog 2; ASXL1, additional sex combs like 1; i(17q), isolated isochromosome 17; SF3B1, splicing factor 3B subunit 1; RARS-T, refractory anemia with ring sideroblasts associated with thrombocytopenia; U2AF1, U2 small nuclear RNA auxiliary factor 1; CMML, chronic myelomonocytic leukemia; SRSF2, serine/arginine-rich splicing factor 2; RUNX1, runt-related transcription factor 1; RAEB-t, refractory anemia with excess blasts in transformation; JAK2, Janus kinase 2; CBL, C-cbl E3 ubiquitin ligase gene; RPS14, ribosomal protein S14.*
ferase from polycomb protein group (PcG) making the catalytic subunit of polycomb repressive complex 2 (PRC2) and inhibiting gene expression via methylation of histone H3 lysine 27 (H3K27). It appears that this protein has the dual role of oncogene and tumor suppressor as both overexpression and loss of function mutations of it are associated with malignancy, especially MDS.

EZH2 mutation has been detected in approximately 6% of MDS patients and is a predictor of poor prognosis for these patients. EZH2 is located on 7q36.1 locus, whereas deletion of chromosome 7 or 7q as the locus of this gene is a common chromosomal abnormality in MDS patients. Therefore, it seems that in addition to mutations involving EZH2, chromosomal abnormalities in chromosome 7 play a role in MDS pathogenesis through the impact on EZH2. Nevertheless, it has been shown in mouse models that mere deletion of EZH2 can induce MDS/MPN like disease. In general, these findings suggest that EZH2 can be a key factor in pathogenesis of MDS, which has a high potential for targeted therapy.

Additional sex combs like 1 (ASXL1): ASXL1 is located on 20q11 locus and is another enzyme involved in histone methylation. ASXL1 causes changes in histones via interaction with PRC2 components such as EZH2. ASXL1 mutation is observed in about 20% of MDS patients and is indicative of poor prognosis in these patients. It was shown that ASXL1 mutation is associated with reduced transformation time of MDS to AML, especially chronic myelomonocytic leukemia (CMML) (62). However, it has recently been reported that ASXL1 results in MDS transformation to AML through mutation in SET binding protein 1 (SETBP1), which prevents its ubiquitination, although other genes like GATA2 and NRAS have been reported in this regard. Understanding the accurate role of ASXL1 pathogenesis needs further investigations.

Splicesome

It was recently shown that mutations (mainly heterozygous) in genes involved in splicing machinery such as Splicing factor 3B subunit 1 (SF3B1), Serine/Arginine-Rich Splicing Factor 2 (SRSF2) and U2 Small Nuclear RNA Auxiliary Factor 1 (U2AF1) play an important role in pathogenesis of myelodysplasia. SF3B1 mutation is the first known mutation in the genes involved in splicing machinery and has an unexpectedly high incidence in Refractory Anaemia with Ring Sideroblasts (RARS) (68-75%) and Refractory anemia with ring sideroblasts associated with marked thrombocytosis (RARS-T) (81%) subtypes, so that it seems to play an important role in pathogenesis of the mentioned subtypes.

SF3B1 mutation will reduce the function of several genes involved in mitochondrial function. Therefore, according to heme synthesis in mitochondria, increase in the number of ringed sideroblasts due to impaired synthesis of heme is a finding frequently observed in patients harboring SF3B1 mutation. However, some studies have indicated the reduced transcription and abnormal splicing of genes associated with heme synthesis, including ABCB7 in presence of SF3B1 mutation. Although SF3B1 mutation is mainly observed in RARS subtype associated with increased platelet count, U2AF1 and SRSF2 mutations are mostly observed in CMML and RAEB1/2 subtypes, and up to 47% of CMML patients have been reported to harbor SRSF2 mutation. SRSF2 mutation is predictor of poor prognosis and accelerated transformation to AML, while the other two mutations have no effect on the outcome of patients.

Others

RUNX1, Janus kinase 2 (JAK2) and C-cbl E3 ubiquitin ligase gene (CBL) are other genes that are commonly mutated in MDS patients. RUNX1 gene (21q22) encodes a subunit of core binding factor (CBF). This transcription factor is commonly dysregulated in hematologic malignancies. RUNX1 mutation is observed in 12% of MDS patients at diagnosis and is generally associated with refractory anemia with excess blasts (RAEB) and refractory anemia with excess blasts in transformation (RAEB-T) subtypes (23.6% of cases). In addition, patients harboring this mutation show a poor prognosis.

JAK2 V617F mutation in hematopoietic stem cells increases the sensitivity to erythropoietin and growth factor independent growth. This mutation is commonly observed in Philadelphia negative myeloproliferative disease (MPD). However, the incidence of this mutation has recently been shown also in MDS patients. Although the incidence of JAK2 V617F mutation is rare in MDS, it is significantly increased in RARS patients, especially RARS with excessive platelets and/or obvious BM fibrosis, showing an approximate 50% incidence in this subgroup. This mutation is also associated with isolated isochromosome 17q. In addition, CBL which encodes an enzyme involved in the degradation of tyrosine kinase receptor, is mutated in MDS patients. JAK2 V617F increases growth signals and proliferation and is associated with poor prognosis.

MDS with del5q

del5q is a better known subtype of MDS observed in 5-10% of cases, which shows severe anemia, neutropenia and normal or increased platelet count with good prognosis. Commonly deleted region (CDR) in 5q includes a region of approximately 1.5Mb that decreases the expression of genes in this region (probably due to haploinsufficiency). These genes include those encoding the Ribosomal Protein S14 (RPS14), SPARC and serine-threonine kinase CSNK1A1 in 7% of cases. Decreased expression of RPS14 was shown to play a vital role in development of anemia (a feature of this subtype), and the induction of its expression can reduce disease symptoms. Allelic exclusion of RPS14 gene disrupts the integrity of mitochondrial membrane, which subsequently leads to the release of ribosomal proteins and nuclear stress, which would result in MDM2 uncoupling and p53 activation. Furthermore, miR145 and miR146 are two important miRNA molecules located in 5q region and highly expressed in HSCs. MIR 145 directly targets MAL/TRAP proteins and FLI1 proteins whereas TRAF6 protein is the main target of miR 146. Knockout of these miRNA molecules showed that although none of them play a role in anemia, miR146 reduction causes neutropenia through increased TRAF6.Reduction of miR145 causes thrombosis via increasing MAL and FLI levels. These findings suggest that haploinsufficiency of RPS14, miR146 and miR145 are responsible for anemia, neutropenia and thrombocytosis in patients with del5q, respectively.

MDS response to drug therapies

Although there have been improvements in treatment of MDS patients, the clinical outcome of patients is still poor. Some studies have provided evidence indicating that the existence of some mutations is associated with response to specific treatments. As mentioned, 5-azacitidine, decitabine, deferasirox and lenelidomide have received FDA approval for treatment of MDS. In relation to p53 mutation, it has been shown that response to treatment with azacitidine is not associated with p53 mutation. However, it appears that patients with del 5q harboring this mutation respond poorly to therapy with lenalidomide. This may be related to therapeutic mechanism of lenalidomide. CSNK1A1 gene on CDR of 5q chromosome encodes casein kinase 1a (CK1a), a tyrosine kinase with a variety of cellular functions. Inhibition of p53 via stabilization of MDM2 and MDMX is one of the most important functions of CK1a. Lenalidomide decreases the level of CK1a pro-
tein; therefore, due to haploinsufficiency of del5q cells for CSNK1A1 gene, these cells are more sensitive to lenalidomide and undergo apoptosis.85 According to these evidences, the therapeutic effect of lenalidomide is expected to decrease in presence of TP53 mutation.

In a study conducted by Bejaret al, it was found that the presence of TET2 mutation is associated with increased response to hypomethylating drugs (HMAs), especially azacitidine, when the ASXL1 gene is not mutated.86 Other studies have also partially confirmed this finding.87

The impact of mutation in the genes involved in splicing process, including SRSF2, U2AF1 and ZRSR2 on response to decitabine was studied by Hong et al. At the end of these trials, no effect on survival and response to this drug was found.88 However, in a large-scale meta-analysis study, it was shown that patients bearing IDH mutation show better response to decitabine relative to other therapies.89 Therefore, decitabine can be an appropriate choice for patients harboring IDH mutation.

The response to HMAs has been associated with some mutations in hematological malignancy. For example, it was reported that AML patients harboring DNMT3A mutation respond well to treatment with decitabine.89 Correlation between RAS mutations and response to treatment of MDS patients was also evaluated in a large study. The results showed that the group harboring mutant and wild type RAS had 43% and 42% response to treatment, respectively. These findings indicate that RAS mutations cause no change in response to existing treatments for MDS.90

Although these data seem to be insufficient for use in clinical practice, further studies in this field can lead to development of a predictive flow chart to choose the best therapeutic approach in patients with different mutations.

**In silico and computer based modeling for treatment and response prediction**

The application of mutations in detection of malignancies is possible only when correlation between them as well as their relationship with different treatments are studied given the complexity of mutations occurring in malignancies. Different bioinformatics methods have been presented that can explore these relationships in a virtual environment and then test different assumptions. In silico modeling is one of the most efficient methods in this regard.

Biophysical and biochemical principles are based on general chemistry and physics laws as well as biological processes and phenomena. Basically, the entire life is a function of chemical and physical interactions between molecules that are not alive but are specific and have relatively complex structures. Advances in computer science and technology have led to development of the idea of identification and construction of these biological processes in virtual environment. Modeling of critical systems is currently a fervent topic of bioinformatics field. This leads to addition of the term *in silico* to dictionary of biological sciences. For example, translation of RNA to protein is a straightforward type of simulation in biological processes.

Intra-computer simulation or *in silico* modeling approaches involve the process of simulating the behavior of living cells and systems.91,92 This method is a first step in structure based and rational drug design and is sometimes referred to as computer-aided drug design. Through in silico techniques, a specific drug is evaluated prior to design by various model building patterns such as QSAR or density functional theory. Similarly, in silico modeling approaches are used to develop cellular and genetic models.93,94 The integration of computer-based modeling approaches into routine techniques can improve detection of cancer and result in the so-called computer-aided diagnostic models. These approaches have been dramatically used in various cancer predictions even in hematologic malignancies such as myeloma.95,96 Information flow between in vitro, in vivo, and in silico approaches is receiving universal appreciation among scientists; thus, their role in cancer research has been highly considered in the last decades (Figure 1).

**Discussion and future prospective**

In this study, we investigate the genetic mutations common in MDS
patients and evaluate their possible role in pathogenesis, prognosis and response to treatment in MDS patients.

The incidence of gene mutations seems to be loosely associated with phenotypic subtype of disease, specific chromosomal abnormalities as well as other mutations.

Mutation in SF3B1 and JAK2 is strongly correlated with the incidence of RARS and RARS-T phenotypes.\(^\text{61,65,78}\) Moreover, RUNX1 mutation rate has been reported to be associated with RAEB and RAEB-T and mutation in SRSF2 and U2AF1 is associated with CMMI.\(^\text{65,73,74}\) This coincidence of different mutations has been reported in some cases. DNMT3A mutation is associated with SF3B1 and U2AF1 and is significantly associated with SRSF2 and ASXL1.\(^\text{75}\) Furthermore, the incidence of IDH mutations is shown to be closely related with ASXL1, SRSF2, and DNMT3A mutations.\(^\text{74}\) EZH2 mutations are also associated with the incidence of RUNX1 in MDS patients.\(^\text{76}\) In addition, SRSF2 and ZRSR2 mutations in patients harboring TET2 mutation as well as U2AF1 mutation are associated with abnormality in chromosome 20 and ASXL1 gene mutation.\(^\text{78}\)

Therefore, further understanding of concurrent genetic mutations as well as their relationship with phenotype of each patient can lead to assessment of different genetic profiles of patients. This will accelerate the detection of molecular abnormalities and reduce the costs of final diagnosis of patients. Given the different responses to treatments with the incidence of gene mutations, the best therapeutic approach for these patients can be ultimately specified. In general, this approach eventually leads to development of an individual-based system of treatment. However, given the above-mentioned complexities, this can only be achieved through bioinformatics modeling systems. It is suggested that in future studies, while searching for further information on the relationship between molecular abnormalities with disease phenotype and response to different drugs, concurrence of mutations with each other is studied to develop computer models to interpret such data.

References


74. Chen CY, Lin LI, Tang JL, et al. RUNX1 gene mutation in primary myelodysplastic syndrome—the mutation can be detected early at diagnosis or acquired during disease progression and is associat-